drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Engineered CAR T cells directed at CD38 using lentiviral transduction; IV infusion with dose escalation; targets CD38+ plasma cell/myeloma malignancies via CAR-mediated T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene-modified T cells transduced (lentiviral) to express a chimeric antigen receptor that binds CD38 on target cells. CAR engagement triggers T‑cell activation and proliferation with cytokine release and perforin/granzyme-mediated cytotoxicity, leading to MHC-independent killing of CD38-positive plasma cell/myeloma malignancies.
drug_name
CD38-directed CAR T cells
nct_id_drug_ref
NCT06849921